Tivantinib, another TKI, is a non-ATP competitive c-MET inhibitor that is being investigated clinically as a highly selective MET inhibitor in NSCLC, hepatocellular carcinoma (HCC), and esophageal cancer. The gene discussed is MET; the disease is hepatocellular carcinoma.